Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2019

View Archived Issues

Nitric oxide-scavenging nanogel suppresses onset of rheumatoid arthritis in vivo

Cell wall component causes trouble in Lyme disease

Going down in flames improves antitumor immunity

Novel protein-coding gene is key to intestinal development

Mutations in SSBP1 gene cause a form of optic atrophy with mitochondrial depletion

Metabolic enzyme targeting takes on pulmonary hypertension

[64Cu]Cu(SarbisPSMA): a bifunctional PSMA ligand for developing PSMA-targeted theranostics

Interim analysis of phase III CASPIAN trial shows improvement in OS in patients treated with Imfinzi

Ovid Therapeutics initiates phase III NEPTUNE trial

Wave Life Sciences initiates DYSTANCE 51 phase II/III study of suvodirsen

Updated phase II data for camrelizumab combination treatment in advanced G/GEJ cancer

Phase I results for fluzoparib in combination with apatinib and paclitaxel in gastric cancer

Researchers link LIG3 mutations to mitochondrial neurogastrointestinal encephalomyopathy

Avaliv Therapeutics divulges new cathepsin D inhibitors

Arena Pharmaceuticals divulges beta3-adrenoceptor antagonists

Sage Therapeutics identifies GABA-A receptor modulators

Galapagos identifies new compounds for HBV

Array BioPharma divulges TAM receptor tyrosine kinases inhibitors

Vaccibody reports immunogenicity data from cancer patients treated with VB10.NEO

CD28 unveiled as potential therapeutic target for giant-cell arteritis

LSK BioPharma reports topline data from phase III study of rivoceranib in advanced gastric cancer

FDA approves Doptelet for chronic immune thrombocytopenia

Darzalex approved by FDA for newly diagnosed multiple myeloma ineligible for ASCT

Phase I/II LuPIN trial of [177Lu]PSMA-617 and NOX-66 in men with mCRPC shows early signs of efficacy

FDA approves Soliris for neuromyelitis optica spectrum disorder

Advaxis to close AIM2CERV trial, focus resources on neoantigen-directed immunotherapies

Verrica initiates phase II study of VP-102 for genital warts

BioCryst opens enrollment in phase I study of oral factor D inhibitor BCX-9930

Ziopharm initiates phase II trial of Controlled IL-12 with cemiplimab in recurrent GBM

ImmuPharma reports open-label extension study results for Lupuzor in SLE

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...